AMEX · Financial Statements
Channel Therapeutics Corporation (CHRO) Financial Statements
$1.35
AMEX: CHRO
Market Cap $8.90M
Overview Financials Dividend Channel Therapeutics Corporation most recently reported annual revenue of $17.0M, net profit of $-43.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $17.0M Operating Profit $-1.0M $-2.0M $-7.0M $-8.0M $0 Net Profit $-1.0M $-2.0M $-7.0M $-8.0M $-43.0M EPS $-0.10 $-0.43 $-1.28 $-1.43 $-23.04 Op Margin — — — — 0.0%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $0 $0 $0 $1.0M $130.0M Total Liabilities $4.0M $4.0M $7.0M $4.0M $92.0M Cash $0 $0 $0 $1.0M $18.0M Borrowings $1.0M $1.0M $1.0M $2.0M $34.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-2.0M $-2.0M $-1.0M $-6.0M $-23.0M Investing Cash Flow $0 $0 $0 $0 $-5.0M Financing Cash Flow $2.0M $1.0M $0 $0 $45.0M Net Cash Flow $0 $0 $0 $0 $18.0M Free Cash Flow $-2.0M $-2.0M $-1.0M $-6.0M $-23.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA -0.07 FCF Yield -397.30% Quick Ratio 1.86 Interest Coverage 15.93 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock